What do Insider Trends Have to Say About Cytokinetics, Incorporated (CYTK)?

Cornelia Mascio
Novembre 25, 2017

At Cytokinetics, Incorporated (CYTK), there are now 154 institutional holders with a total of 39,788,671 shares. Morgan Stanley initiated coverage on Cytokinetics, in a report on Monday, July 31st. They issued an overweight rating and a $24.00 price objective for the company. Cytokinetics, presently has a consensus rating of Buy and a consensus target price of $17.64.

Cantor Fitzgerald "Downgrades" Cytokinetics (NASDAQ:CYTK) in a research note issued to investors on 11/22/17 to Neutral with price target of $0. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company's stock. The stock has an average rating of Buy and an average target price of $17.64.

Cytokinetics, Incorporated (NASDAQ:CYTK)'s short interest is 4.26 million shares, or 13.29% of the float.

Cytokinetics Inc has a 52 week low of $8.77 and a 52 week high of $17.20 The company's market cap is now $0. The consensus mean EPS for the current quarter is at $-0.69 derived from a total of 7 estimates from the analysts who have weighed in on projected earnings. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.64) by $0.04. Return on Equity (ROE) stands at -62.6% and Return on Investment (ROI) of 15 percent. The business had revenue of $6.18 million during the quarter, compared to analyst estimates of $5.35 million. equities analysts forecast that Cytokinetics, will post -2.4 earnings per share for the current fiscal year.

Institutions own 73.84% of Cytokinetics, Incorporated (CYTK)'s shares. If you are reading this report on another publication, it was illegally stolen and republished in violation of US & worldwide copyright legislation.

Cytokinetics, Incorporated, launched on August 5, 1997, is a late-stage biopharmaceutical company.

In related news, SVP Bradley Paul Morgan sold 118,330 shares of Cytokinetics, stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $15.00, for a total value of $1,774,950.00. Following the completion of the transaction, the director now owns 5,000 shares of the company's stock, valued at approximately $70,000. The disclosure for this sale can be found here. In the last 12 months, there have been 9 open market buys by insiders and 28 sells for a total of 37 insider trades. Following the completion of the sale, the insider now owns 17,982 shares in the company, valued at approximately $232,687.08. In third place is VANGUARD GROUP INC with 3,387,871 shares held. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company's stock worth $161,000 after acquiring an additional 13,036 shares in the last quarter. State of Alaska Department of Revenue bought a new position in shares of Cytokinetics, in the 2nd quarter worth about $109,000. Mcdowell now owns $186,156 of the stock per the Form 4 SEC filing. Municipal Employees Retirement System of MI bought a new position in shares of Cytokinetics, in the 2nd quarter worth about $132,000. This works out to a net increase in ownership of 1.3 million shares, and suggests that institutions are feeling bullish about the stock. Birchview Capital LP bought a new position in shares of Cytokinetics, in the 3rd quarter worth about $145,000. Finally, Citigroup Inc. lifted its stake in Cytokinetics, by 9.9% in the second quarter. Teachers Advisors LLC now owns 60,326 shares of the biopharmaceutical company's stock valued at $775,000 after purchasing an additional 7,048 shares during the last quarter.

When it comes to institutional holdings, taking a look at a public company's active positions is a useful way to understand how institutional investors view the value of the stock.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE